These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6388105)

  • 21. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
    Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
    Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional assessment of immune markers of graft rejection: a comprehensive study in live-related donor renal transplantation.
    Panigrahi A; Deka R; Bhowmik D; Dash SC; Tiwari SC; Guleria S; Mehta SN; Mehra NK
    Clin Transplant; 2006; 20(1):85-90. PubMed ID: 16556160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
    Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
    [No Abstract]   [Full Text] [Related]  

  • 25. Human renal allograft and peripheral blood T lymphocyte subpopulations during the onset and treatment of rejection.
    Taube D; Welsh K; Hobby P; Williams DG
    Clin Nephrol; 1984 Sep; 22(3):127-32. PubMed ID: 6237816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.
    Wagrowska-Danilewicz M; Danilewicz M
    Nefrologia; 2003; 23(6):538-44. PubMed ID: 15002789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody.
    Waid TH; Lucas BA; Thompson JS; Brown S; Moore D; Amlot P; Janossy G
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1778-84. PubMed ID: 2652582
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E-rosette forming cell numbers in the blood of human renal allograft recipients.
    Kelly GE; Sheil AG
    Clin Exp Immunol; 1977 Mar; 27(3):454-63. PubMed ID: 324670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells.
    Reinke P; Fietze E; Döcke WD; Kern F; Ewert R; Volk HD
    Transplantation; 1994 Jul; 58(1):35-41. PubMed ID: 7913561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood group Lewis alloantibodies cause antibody-mediated rejection in renal transplant recipients.
    Boratyńska M; Banasik M; Hałoń A; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2711-4. PubMed ID: 18021965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
    Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
    Transplantation; 2005 Aug; 80(4):546-54. PubMed ID: 16220623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunosuppression with monoclonal antibodies. A model to determine the rules for effective serotherapy.
    Cobbold SP; Thierfelder S; Waldmann H
    Mol Biol Med; 1983 Oct; 1(3):285-304. PubMed ID: 6209527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody.
    Kirkman RL; Araujo JL; Busch GJ; Carpenter CB; Milford EL; Reinherz EL; Schlossman SF; Strom TB; Tilney NL
    Transplantation; 1983 Dec; 36(6):620-6. PubMed ID: 6197792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of immunomodulation on peripheral T cell subsets.
    Chatenoud L; Berrih S; Bene MC; Kreis H; Bach JF
    J Clin Immunol; 1982 Jul; 2(3 Suppl):61S-66S. PubMed ID: 6290529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-Leu2a (anti-CD8) monoclonal antibody therapy: antibody-mediated cell clearance in vivo requires Fc-FcRII interaction.
    Wee SL; Phelan JM; Preffer FI; Colvin RB; Cosimi AB
    Transplant Proc; 1989 Feb; 21(1 Pt 1):117-8. PubMed ID: 2495592
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic use of monoclonal antibodies in kidney transplantation.
    Kreis H; Chkoff N; Vigeral P; Chatenoud L; Lacombe M; Campos H; Pruna A; Goldstein G; Bach JF; Crosnier J
    Adv Nephrol Necker Hosp; 1985; 14():389-407. PubMed ID: 3919540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.